Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 638 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with... April 26, 2023 An Important Part of Cancer Caregiving That’s Often Overlooked and How... September 9, 2021 Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... March 18, 2025 After a Breast Cancer Diagnosis, Men May Be More Likely to... October 2, 2019 Load more HOT NEWS Does Eating Processed Meat Increase Your Risk for Cancer? 11 top tips for cutting back on alcohol Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma
